Skip to main content
OpenTrials
Completed

NCT Number: NCT04169815

Access Natriuretic Peptide Assay(s) Pivotal - Emergency Department Subject Enrollment and Specimen Collection

The purpose of the pivotal study is to collect blood specimens and clinical data from patients suspected of having Heart Failure (HF), which will be tested at a future date on Natriuretic Peptide assay(s) to validate diagnostic cutoffs and assess HF severity.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Beckman Coulter Site AJ, Loma Linda, California, United States

Loading trial locations.

About this study

A prospective clinical sample collection and future natriuretic peptide testing will be conducted in an emergency department only population. Patients presenting to the Emergency Department (ED) with signs and symptoms of acute heart failure will be approached for enrollment.

Clinical and laboratory data will be collected to establish product performance and clinical concordance to adjudicated clinical diagnosis. Approximately 1800 evaluable subjects at geographically dispersed sites in the US will be enrolled in the study.

Sample collection and testing of clinical samples with the Access Natriuretic Peptide assay will be performed under two separate protocols

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed and dated informed consent obtained
  • Adult aged 21 years or older
  • Presenting with a clinical suspicion of acute HF
  • Subject clinical history available for review by Sponsor or delegates and FDA or other regulatory agencies

Exclusion criteria

  • Dyspnea clearly not secondary to HF (e.g. primary lung disease or chest trauma)
  • Stage 4 or 5 Chronic Kidney Disease (CKD)
  • Chronic dialysis
  • Participation in a clinical study that may interfere with participation in this study
  • Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.

Treatment and study plan

Access Immunodiagnostic Products

Diagnostic Test

Access Natriuretic Peptide Assay

Primary outcomes

  1. Sensitivity and Specificity of the future Natriuretic Peptide Assay(s)

    Time frame: Single blood draw upon study entry at day 1

    Establish the performance of the future Natriuretic Peptide assay(s) against the adjudicated diagnosis.

Secondary outcomes

  1. Heart Failure Severity Assessment

    Time frame: Single blood draw upon study entry at day 1 and two remote follow up visits

    Demonstrate that the Access Natriuretic Peptide Assay may be used for assessment of heart failure severity.

Sponsors and collaborators

Lead sponsor

Beckman Coulter, Inc.

Industry

Registry information

Official study title

Pivotal Evaluation of the Access Natriuretic Peptdie Assay(s) as an Aid in the Diagnosis and Assessment of Severity of Acute Heart Failure - Emergency Department Subject Enrollment and Specimen Collection

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Nov 20, 2019
Registry last updated
Feb 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.